{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:42:35Z","timestamp":1771231355281,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In 2016, the WHO included haemoglobin values within normal ranges as a diagnostic criterion for Polycythaemia Vera (PV). Since then, concerns have arisen that a large number of patients are undergoing unnecessary screening for PV. To address this issue, we estimated the prevalence of <jats:italic>JAK2<\/jats:italic> p.V617F in individuals with elevated haemoglobin or haematocrit and developed and validated a screening algorithm for PV. A total of 15,366 blood counts performed in seven non-consecutive days were reviewed, of which 1001 were selected for subsequent <jats:italic>JAK2<\/jats:italic> p.V617F mutation screening. Eight (0.8%) new <jats:italic>JAK2<\/jats:italic> p.V617F-mutated cases were detected. From ROC curves, a two-step algorithm was developed based on the optimal cut-off for the detection of the <jats:italic>JAK2<\/jats:italic> p.V617F mutation. The algorithm was prospectively validated in an independent cohort of 15,298 blood counts. A total of 1595 (10.4%) cases met the criterion for haemoglobin or haematocrit, of whom 581 passed to step 2 (3.8% of the total). The <jats:italic>JAK2<\/jats:italic> p.V617F mutation was detected in 7 of the 501 patients tested, which accounts for 0.04% of the total cohort and 0.4% of patients with erythrocytosis. In conclusion, this data show that our two-step algorithm improves the selection of candidates for <jats:italic>JAK2<\/jats:italic> p.V617F testing.<\/jats:p>","DOI":"10.1038\/s41598-020-80459-y","type":"journal-article","created":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T11:19:34Z","timestamp":1610104774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development and validation of a sequential two-step algorithm for the screening of individuals with potential polycythaemia vera"],"prefix":"10.1038","volume":"11","author":[{"given":"Miguel","family":"Piris-Villaespesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"Saez-Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Nu\u00f1ez-Torr\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Mu\u00f1oz-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco J.","family":"del Castillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Villarrubia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Lopez-Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquin","family":"Martinez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Garcia-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"issue":"20","key":"80459_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber, D. A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20), 2391\u20132405 (2016).","journal-title":"Blood"},{"issue":"11","key":"80459_CR2","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3324\/haematol.2012.067348","volume":"97","author":"A Alvarez-Larran","year":"2012","unstructured":"Alvarez-Larran, A. et al. Red cell mass measurement in patients with clinically suspected diagnosis of polycythemia vera or essential thrombocythemia. Haematologica 97(11), 1704\u20131707 (2012).","journal-title":"Haematologica"},{"issue":"4","key":"80459_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/ajcp\/aqw131","volume":"146","author":"L Busque","year":"2016","unstructured":"Busque, L. et al. Laboratory investigation of myeloproliferative neoplasms (MPNs): Recommendations of the Canadian MPN group. Am. J. Clin. Pathol. 146(4), 408\u2013422 (2016).","journal-title":"Am. J. Clin. Pathol."},{"issue":"5","key":"80459_CR4","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/ijlh.12686","volume":"39","author":"AF Sandes","year":"2017","unstructured":"Sandes, A. F., Gon\u00e7alves, M. V. & de Chauffaille, M. Frequency of polycythemia in individuals with normal complete blood cell counts according to the new 2016 WHO classification of myeloid neoplasms. Int. J. Lab. Hematol. 39(5), 528\u2013531 (2017).","journal-title":"Int. J. Lab. Hematol."},{"issue":"6","key":"80459_CR5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","volume":"129","author":"E Rumi","year":"2017","unstructured":"Rumi, E. & Cazzola, M. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood 129(6), 680\u2013692 (2017).","journal-title":"Blood"},{"issue":"5","key":"80459_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/ajh.24684","volume":"92","author":"T Barbui","year":"2017","unstructured":"Barbui, T. et al. Diagnostic impact of the 2016 revised who criteria for polycythemia vera. Am. J. Hematol. 92(5), 417\u2013419 (2017).","journal-title":"Am. J. Hematol."},{"issue":"26","key":"80459_CR7","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371(26), 2488\u20132498 (2014).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"80459_CR8","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377(2), 111\u2013121 (2017).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"80459_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood.2019001113","volume":"134","author":"S Cordua","year":"2019","unstructured":"Cordua, S. et al. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood 134(5), 469\u2013479 (2019).","journal-title":"Blood"},{"issue":"1","key":"80459_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bjh.12099","volume":"160","author":"C Nielsen","year":"2013","unstructured":"Nielsen, C., Birgens, H. S., Nordestgaard, B. G. & Bojesen, S. E. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49,488 individuals from the general population. Br. J. Haematol. 160(1), 70\u201379 (2013).","journal-title":"Br. J. Haematol."},{"issue":"8","key":"80459_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.celrep.2015.02.005","volume":"10","author":"T McKerrell","year":"2015","unstructured":"McKerrell, T. et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 10(8), 1239\u20131245 (2015).","journal-title":"Cell Rep."},{"issue":"1","key":"80459_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1182\/blood-2006-03-009472","volume":"109","author":"X Xu","year":"2007","unstructured":"Xu, X. et al. JAK2V617F: Prevalence in a large Chinese hospital population. Blood 109(1), 339\u2013342 (2007).","journal-title":"Blood"},{"key":"80459_CR13","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1016\/j.ejim.2018.03.017","volume":"52","author":"SE Langabeer","year":"2018","unstructured":"Langabeer, S. E. An increase in diagnostic JAK2 V617F mutation testing: Is masked polycythaemia vera the explanantion?. Eur. J. Intern. Med. 52, e37\u2013e38 (2018).","journal-title":"Eur. J. Intern. Med."},{"issue":"9","key":"80459_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00277-008-0512-x","volume":"87","author":"I Rapado","year":"2008","unstructured":"Rapado, I. et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann. Hematol. 87(9), 741\u2013749 (2008).","journal-title":"Ann. Hematol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80459-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80459-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T01:07:32Z","timestamp":1670029652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-80459-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["80459"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-80459-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"209"}}